Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3064829 | Journal of Neuroimmunology | 2010 | 11 Pages |
Abstract
We studied the effects of combination treatment with an anti-inflammatory agent, interferon (IFN)-β, and a putative neuroprotective agent, an estrogen receptor (ER)-β ligand, during EAE. Combination treatment significantly attenuated EAE disease severity, preserved axonal densities in spinal cord, and reduced CNS inflammation. Combining ERβ treatment with IFNβ reduced IL-17, while it abrogated IFNβ-mediated increases in Th1 and Th2 cytokines from splenocytes. Additionally, combination treatment reduced VLA-4 expression on CD4+ T cells, while it abrogated IFNβ-mediated decreases in MMP-9. Our data demonstrate that combination treatments can result in complex effects that could not have been predicted based on monotherapy data alone.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sienmi Du, Francisco Sandoval, Pauline Trinh, Rhonda R. Voskuhl,